{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:41:27Z","timestamp":1772469687317,"version":"3.50.1"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Although mostly incurable, indolent non-Hodgkin lymphomas (iNHL) are chronic diseases with a median overall survival approaching 20 years. In recent years, important advances in the knowledge of the biology of these lymphomas have led to the development of new drugs, mostly chemotherapy-free, with promising outcomes. With a median age of around 70 years at diagnosis, many patients with iNHL suffer from comorbid conditions that may limit treatment options. Therefore, nowadays, in the transition towards personalized medicine, several challenges lie ahead, such as identifying predictive markers for the selection of treatment, the adequate sequencing of available therapies, and the management of new and accumulated toxicities. In this review, we include a perspective on recent therapeutic advances in follicular and marginal zone lymphoma. We describe emerging data on approved and emerging novel therapies, such as targeted therapies (PI3K inhibitors, BTK inhibitors, EZH2 inhibitors), monoclonal antibodies and antibody-drug conjugates. Finally, we describe immune-directed approaches such as combinations with lenalidomide or the even more innovative bispecific T-cell engagers and chimeric antigen receptor T-cell therapy, which can achieve a high rate of durable responses with manageable toxicities, further obviating the need for chemotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2023.1170394","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:26:04Z","timestamp":1683091564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review"],"prefix":"10.3389","volume":"13","author":[{"given":"Andrea","family":"Rivero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Mozas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"B1","unstructured":"Follicular lymphoma"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.936013","article-title":"Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma","volume":"56","author":"Olszewski","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish lymphoma registry study","volume":"29","author":"Junl\u00e9n","year":"2015","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience","author":"Mozas","year":"2020","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the united states: data from the observational national LymphoCare study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. a retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the national LymphoCare study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in patients with mucosa-associated lymphoid tissue lymphoma receiving systemic treatment","volume":"105","author":"Conconi","year":"2020","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"B26","article-title":"Biology of fol lic u lar lym phoma : insights and win dows of clin i cal oppor tu nity","author":"Perrett","year":""},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012386","article-title":"Genetic and phenotypic attributes of splenic marginal zone lymphoma","volume":"139","author":"Bonfiglio","year":"2022","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04470-7","article-title":"Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma","volume":"100","author":"Mozas","year":"2021","journal-title":"Ann Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03f5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134869","article-title":"Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma (CITADEL-203)","volume":"136","author":"Lynch","year":"2020","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134451","article-title":"Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204)","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.15_suppl.7549","article-title":"Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL)","volume":"36","author":"Fowler","year":"2018","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in Relapsed\/Refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16424","article-title":"The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma","volume":"189","author":"Fowler","year":"2020","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus r- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005588","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-166991","article-title":"Tazemetostat in combination with lenalidomide and rituximab in patients with Relapsed\/Refractory follicular lymphoma: phase 1b results of symphony-1","volume":"140","author":"Batlevi","year":"2022","journal-title":"Blood"},{"key":"B49","unstructured":"FDA Investigating possible increased risk of death with lymphoma medicine ukoniq (umbralisib)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00333-3","article-title":"Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory b-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial","volume":"23","author":"Pagel","year":"2022","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.01.018","article-title":"ABT-199: taking dead aim at BCL-2","volume":"23","author":"Davids","year":"2013","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145217","article-title":"Phase II study of venetoclax in combination with obinutuzumab and bendamustine in patients with high tumor burden follicular lymphoma as front line therapy (PrECOG 0403)","author":"Portell","year":"2021","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00539-8","article-title":"Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: final analysis of a phase Ib\/II trial","author":"Morschhauser","year":"2021","journal-title":"Blood Cancer J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume-title":"Journal of clinical oncology","author":"Leonard","year":"2019"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145640","article-title":"Completed induction phase analysis of magnify: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in Relapsed\/Refractory indolent non-Hodgkin lymphoma","volume":"138","author":"Lansigan","year":"2021","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1182\/blood-2019-129422","article-title":"Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL)","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/blood-2019-131045","article-title":"A phase I\/II study of lenalidomide plus obinutuzumab in relapsed indolent lymphoma","volume":"134","author":"Fowler","year":"2019","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory b-cell non- hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","author":"Diefenbach","year":"2021","journal-title":"Lancet Haematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory b-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157691","article-title":"Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with Relapsed\/Refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study","volume":"140","author":"Bartlett","year":"2022","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-Cell-Engaging bispecific antibody, induces durable complete remissions in relapsed or refractory b-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory b-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158232","article-title":"Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R2) for first-line treatment of follicular lymphoma: initial results from phase 1\/2 trial","volume":"140","author":"Falchi","year":"2022","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive b-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158406","article-title":"Odronextamab in patients with Relapsed\/Refractory (R\/R) diffuse Large b-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566","article-title":"Chimeric antigen receptor T cells in refractory b-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/hon.96_2629","article-title":"Cd19-directed car T cell therapy (Ctl019) for Relapsed\/Refractory diffuse Large b-cell and follicular lymphomas: four year outcomes","volume":"37","author":"Chong","year":"2019","journal-title":"Hematol Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006240","article-title":"Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma","volume":"6","author":"Nastoupil","year":"2022","journal-title":"Blood Adv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in b-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-hodgkin\u2019s lymphoma","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"B85","doi-asserted-by":"crossref","unstructured":"LeonardJ\n          Five-year results and overall survival update from the phase 3 randomized study augment: lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with Relapsed\/Refractory indolent non-Hodgkin lymphoma2022","DOI":"10.1182\/blood-2022-158631"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.10.372","article-title":"INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED\/REFRACTORY (R\/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)","author":"Andorsky","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for b cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_","article-title":"HEMATOLOGIC MALIGNANCIES incorporating novel targeted and immunotherapeutic agents in the treatment of b-cell lymphomas","author":"Shah","year":"2021"},{"key":"B89","article-title":"Follicular lymphoma: a focus on current and emerging therapies","author":"Cahill","year":""},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S267258","article-title":"Chemotherapy-free management of follicular and marginal zone lymphoma","volume":"13","author":"Ollila","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_279043","article-title":"ADCs, BiTEs, CARs, and small molecules: a new era of targeted therapy in non-Hodgkin lymphoma","author":"Abramson","year":"2020","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large b-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase i study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with\/without rituximab in patients with relapsed\/refractory b-cell non-hodgkin lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B96","volume-title":"Indolent lymphomas: pushing the pace with novel agents","author":"Jacobson","year":"2019"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994\/1928283\/blood.2021011994.pdf","article-title":"Bispecific antibodies for the treatment of b-cell lymphoma: promises, unknowns and opportunities bispecific antibodies for the treatment of b-cell lymphoma: promises, unknowns, and opportunities","author":"Falchi","year":""},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/Lenalidomide in Relapsed\/Refractory non-hodgkin\u2019s lymphoma: a phase I California cancer consortium study of safety, efficacy and immune correlative analysis","author":"Poh","year":"2019","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.7524","article-title":"Subcutaneous epcoritamab with rituximab + lenalidomide (R 2 ) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): update from phase 1\/2 trial","volume":"40","author":"Falchi","year":"2022","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158203","article-title":"Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular Lymphoma:Phase 1\/2 trial update","volume":"140","author":"Falchi","year":"2022","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159586","article-title":"A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with Relapsed\/Refractory non-hodgkin\u2019s lymphoma: recommended dose Safety\/Efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163235","article-title":"Pharmacodynamics and biomarker correlates of imvotamab (IGM-2323), the first-in-Class CD20xCD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced b cell malignancies","volume":"140","author":"Hernandez","year":"2022","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.5_suppl.120","article-title":"High durable CR rates and preliminary safety profile for JCAR017 in R\/R aggressive b-NHL (TRANSCEND NHL 001 study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-134362","article-title":"Long-term survival and gradual recovery of b cells in patients with refractory Large b-cell lymphoma treated with axicabtagene ciloleucel","volume":"19","author":"Jacobson","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for Large b-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive b-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large b-cell lymphoma (TRANSFORM): results from an interim analysi","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2030164","article-title":"Five-year outcomes for refractory b-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"B112","unstructured":"FDA Grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma"},{"key":"B113","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-158024","volume-title":"Long-term clinical outcomes and correlative efficacy analyses in patients (Pts) with Relapsed\/Refractory follicular lymphoma (r\/r FL) treated with tisagenlecleucel in the elara trial","author":"Dreyling","year":"2022"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.022","article-title":"Assessment of healthcare resource utilization and hospitalization costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with tisagenlecleucel: results from the ELARA study","volume":"29","author":"Fowler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.56.1","article-title":"Follicular lymphoma: the role of the tumor microenvironment in prognosis","volume":"56","author":"Sugimoto","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Lopez-Guillermo","year":"2009","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.258426","article-title":"A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade","volume":"106","author":"Miller","year":"2021","journal-title":"Haematologica"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B123","volume-title":"Session 4 \u2013 treatment with novel antibodies the first-in-Class anti-Cd47 antibody Hu5F9-G4 + rituximab induces durable responses in relapsed \/ refractory dlbcl and indolent Lymphoma : interim phase clinical activity of Regn1979 , an anti-Cd20 X anti-Cd3 b. :89-90","year":""},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135941","article-title":"ALX148, a CD47 blocker, in combination with rituximab in patients with non-Hodgkin lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153683","article-title":"CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-Human dose escalation study","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1170394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:26:11Z","timestamp":1683091571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1170394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":125,"alternative-id":["10.3389\/fonc.2023.1170394"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1170394","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"article-number":"1170394"}}